ATC code L01

Quality 0.50 · 0 views · Updated 2 months ago

Pharmaceutical drug classification

title: "ATC code L01" type: doc version: 1 created: 2026-02-28 author: "Wikipedia contributors" status: active scope: public tags: ["atc-codes", "antineoplastic-drugs"] description: "Pharmaceutical drug classification" topic_path: "general/atc-codes" source: "https://en.wikipedia.org/wiki/ATC_code_L01" license: "CC BY-SA 4.0" wikipedia_page_id: 0 wikipedia_revision_id: 0

::summary Pharmaceutical drug classification ::

L01A Alkylating agents

L01B Antimetabolites

L01BA Folic acid analogues

:L01BA01 Methotrexate :L01BA03 Raltitrexed :L01BA04 Pemetrexed :L01BA05 Pralatrexate

L01BB Purine analogues

:L01BB02 Mercaptopurine :L01BB03 Tioguanine :L01BB04 Cladribine :L01BB05 Fludarabine :L01BB06 Clofarabine :L01BB07 Nelarabine :QL01BB90 Rabacfosadine

L01BC Pyrimidine analogues

:L01BC01 Cytarabine :L01BC02 Fluorouracil :L01BC03 Tegafur :L01BC04 Carmofur :L01BC05 Gemcitabine :L01BC06 Capecitabine :L01BC07 Azacitidine :L01BC08 Decitabine :L01BC09 Floxuridine :L01BC52 Fluorouracil, combinations :L01BC53 Tegafur, combinations :L01BC58 Decitabine, combinations :L01BC59 Trifluridine, combinations

L01C Plant alkaloids and other natural products

L01CA Vinca alkaloids and analogues

:L01CA01 Vinblastine :L01CA02 Vincristine :L01CA03 Vindesine :L01CA04 Vinorelbine :L01CA05 Vinflunine :L01CA06 Vintafolide

L01CB Podophyllotoxin derivatives

:L01CB01 Etoposide :L01CB02 Teniposide

L01CC Colchicine derivatives

:L01CC01 Demecolcine

L01CD Taxanes

:L01CD01 Paclitaxel :L01CD02 Docetaxel :L01CD03 Paclitaxel poliglumex :L01CD04 Cabazitaxel :L01CD51 Paclitaxel and encequidar

L01CE Topoisomerase 1 (TOP1) inhibitors

:L01CE01 Topotecan :L01CE02 Irinotecan :L01CE03 Etirinotecan pegol :L01CE04 Belotecan

L01CX Other plant alkaloids and natural products

:L01CX01 Trabectedin

L01D Cytotoxic antibiotics and related substances

L01DA Actinomycines

:L01DA01 Dactinomycin

L01DB Anthracyclines and related substances

:L01DB01 Doxorubicin :L01DB02 Daunorubicin :L01DB03 Epirubicin :L01DB04 Aclarubicin :L01DB05 Zorubicin :L01DB06 Idarubicin :L01DB07 Mitoxantrone :L01DB08 Pirarubicin :L01DB09 Valrubicin :L01DB10 Amrubicin :L01DB11 Pixantrone

L01DC Other cytotoxic antibiotics

:L01DC01 Bleomycin :L01DC02 Plicamycin :L01DC03 Mitomycin :L01DC04 Ixabepilone :L01DC05 Utidelone

L01E Protein kinase inhibitors

L01EA BCR-ABL tyrosine kinase inhibitors

:L01EA01 Imatinib :L01EA02 Dasatinib :L01EA03 Nilotinib :L01EA04 Bosutinib :L01EA05 Ponatinib :L01EA06 Asciminib

L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors

:L01EB01 Gefitinib :L01EB02 Erlotinib :L01EB03 Afatinib :L01EB04 Osimertinib :L01EB05 Rociletinib :L01EB06 Olmutinib :L01EB07 Dacomitinib :L01EB08 Icotinib :L01EB09 Lazertinib :L01EB10 Mobocertinib :L01EB11 Aumolertinib :L01EB12 Firmonertinib

L01EC B-Raf serine-threonine kinase (BRAF) inhibitors

:L01EC01 Vemurafenib :L01EC02 Dabrafenib :L01EC03 Encorafenib :L01EC04 Tovorafenib

L01ED Anaplastic lymphoma kinase (ALK) inhibitors

:L01ED01 Crizotinib :L01ED02 Ceritinib :L01ED03 Alectinib :L01ED04 Brigatinib :L01ED05 Lorlatinib

L01EE Mitogen-activated protein kinase (MEK) inhibitors

:L01EE01 Trametinib :L01EE02 Cobimetinib :L01EE03 Binimetinib :L01EE04 Selumetinib :L01EE05 Mirdametinib :L01EE06 Tunlametinib

L01EF Cyclin-dependent kinase (CDK) inhibitors

:L01EF01 Palbociclib :L01EF02 Ribociclib :L01EF03 Abemaciclib

L01EG Mammalian target of rapamycin (mTOR) kinase inhibitors

:L01EG01 Temsirolimus :L01EG02 Everolimus :L01EG03 Ridaforolimus :L01EG04 Sirolimus

L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors

:L01EH01 Lapatinib :L01EH02 Neratinib :L01EH03 Tucatinib :L01EH04 Zongertinib :L01EH05 Mifanertinib :L01EH06 Sevabertinib

L01EJ Janus-associated kinase (JAK) inhibitors

:L01EJ01 Ruxolitinib :L01EJ02 Fedratinib :L01EJ03 Pacritinib :L01EJ04 Momelotinib

L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors

:L01EK01 Axitinib :L01EK02 Cediranib :L01EK03 Tivozanib :L01EK04 Fruquintinib :L01EK05 Rivoceranib

L01EL Bruton's tyrosine kinase (BTK) inhibitors

:L01EL01 Ibrutinib :L01EL02 Acalabrutinib :L01EL03 Zanubrutinib :L01EL04 Orelabrutinib :L01EL05 Pirtobrutinib :L01EL06 Tirabrutinib

L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors

:L01EM01 Idelalisib :L01EM02 Copanlisib :L01EM03 Alpelisib :L01EM04 Duvelisib :L01EM05 Parsaclisib :L01EM06 Inavolisib

L01EN Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors

:L01EN01 Erdafitinib :L01EN02 Pemigatinib :L01EN03 Infigratinib :L01EN04 Futibatinib

L01EP Cellular-mesenchymal-epithelial transition factor (c-MET) kinase inhibitors

:L01EP01 Capmatinib :L01EP02 Tepotinib :L01EP03 Savolitinib

L01EX Other protein kinase inhibitors

:L01EX01 Sunitinib :L01EX02 Sorafenib :L01EX03 Pazopanib :L01EX04 Vandetanib :L01EX05 Regorafenib :L01EX06 Masitinib :L01EX07 Cabozantinib :L01EX08 Lenvatinib :L01EX09 Nintedanib :L01EX10 Midostaurin :L01EX11 Quizartinib :L01EX12 Larotrectinib :L01EX13 Gilteritinib :L01EX14 Entrectinib :L01EX15 Pexidartinib :L01EX18 Avapritinib :L01EX19 Ripretinib :L01EX22 Selpercatinib :L01EX23 Pralsetinib :L01EX24 Surufatinib :L01EX25 Umbralisib :L01EX26 Sitravatinib :L01EX27 Capivasertib :L01EX28 Repotrectinib :L01EX29 Vimseltinib :QL01EX90 Toceranib

L01F Monoclonal antibodies and antibody drug conjugates

L01FA CD20 (clusters of differentiation 20) inhibitors

:L01FA01 Rituximab :L01FA02 Ofatumumab :L01FA03 Obinutuzumab

L01FB CD22 (clusters of differentiation 22) inhibitors

:L01FB01 Inotuzumab ozogamicin :L01FB02 Moxetumomab pasudotox

L01FC CD38 (clusters of differentiation 38) inhibitors

:L01FC01 Daratumumab :L01FC02 Isatuximab

L01FD HER2 (human epidermal growth factor receptor 2) inhibitors

:L01FD01 Trastuzumab :L01FD02 Pertuzumab :L01FD03 Trastuzumab emtansine :L01FD04 Trastuzumab deruxtecan :L01FD05 Trastuzumab duocarmazine :L01FD06 Margetuximab :L01FD07 Zanidatamab

L01FE EGFR (epidermal growth factor receptor) inhibitors

:L01FE01 Cetuximab :L01FE02 Panitumumab :L01FE03 Necitumumab

L01FF PD-1/PDL-1 (programmed cell death protein 1/ death ligand 1) inhibitors

:L01FF01 Nivolumab :L01FF02 Pembrolizumab :L01FF03 Durvalumab :L01FF04 Avelumab :L01FF05 Atezolizumab :L01FF06 Cemiplimab :L01FF07 Dostarlimab :L01FF08 Prolgolimab :L01FF09 Tislelizumab :L01FF10 Retifanlimab :L01FF11 Sugemalimab :L01FF12 Serplulimab :L01FF13 Toripalimab :L01FF14 Camrelizumab :L01FF15 Envafolimab :L01FF16 Sasanlimab

L01FG VEGF/VEGFR (vascular endothelial growth factor) inhibitors

:L01FG01 Bevacizumab :L01FG02 Ramucirumab

L01FX Other monoclonal antibodies and antibody drug conjugates

:L01FX01 Edrecolomab :L01FX02 Gemtuzumab ozogamicin :L01FX03 Catumaxomab :L01FX04 Ipilimumab :L01FX05 Brentuximab vedotin :L01FX06 Dinutuximab beta :L01FX07 Blinatumomab :L01FX08 Elotuzumab :L01FX09 Mogamulizumab :L01FX10 Olaratumab :L01FX11 Bermekimab :L01FX12 Tafasitamab :L01FX13 Enfortumab vedotin :L01FX14 Polatuzumab vedotin :L01FX15 Belantamab mafodotin :L01FX16 Oportuzumab monatox :L01FX17 Sacituzumab govitecan :L01FX18 Amivantamab :L01FX19 Sabatolimab :L01FX20 Tremelimumab :L01FX21 Naxitamab :L01FX22 Loncastuximab tesirine :L01FX23 Tisotumab vedotin :L01FX24 Teclistamab :L01FX25 Mosunetuzumab :L01FX26 Mirvetuximab soravtansine :L01FX27 Epcoritamab :L01FX28 Glofitamab :L01FX29 Talquetamab :L01FX31 Zolbetuximab :L01FX32 Elranatamab :L01FX33 Tarlatamab :L01FX34 Odronextamab :L01FX35 Datopotamab deruxtecan :L01FX36 Patritumab deruxtecan :L01FX37 Linvoseltamab :L01FX38 Ifinatamab deruxtecan :L01FX39 Bemarituzumab

L01FY Combinations of monoclonal antibodies and antibody drug conjugates

:L01FY01 Pertuzumab and trastuzumab :L01FY02 Nivolumab and relatlimab :L01FY03 Prolgolimab and nurulimab

L01X Other antineoplastic agents

L01XA Platinum compounds

:L01XA01 Cisplatin :L01XA02 Carboplatin :L01XA03 Oxaliplatin :L01XA04 Satraplatin :L01XA05 Polyplatillen

L01XB Methylhydrazines

:L01XB01 Procarbazine

L01XD Sensitizers used in photodynamic/radiation therapy

:L01XD01 Porfimer sodium :L01XD03 Methyl aminolevulinate :L01XD04 Aminolevulinic acid :L01XD05 Temoporfin :L01XD06 Efaproxiral :L01XD07 Padeliporfin

L01XF Retinoids for cancer treatment

:L01XF01 Tretinoin :L01XF02 Alitretinoin :L01XF03 Bexarotene

L01XG Proteasome inhibitors

:L01XG01 Bortezomib :L01XG02 Carfilzomib :L01XG03 Ixazomib

L01XH Histone deacetylase (HDAC) inhibitors

:L01XH01 Vorinostat :L01XH02 Romidepsin :L01XH03 Panobinostat :L01XH04 Belinostat :L01XH05 Entinostat :L01XH06 Tucidinostat :L01XH07 Resminostat

L01XJ Hedgehog pathway inhibitors

:L01XJ01 Vismodegib :L01XJ02 Sonidegib :L01XJ03 Glasdegib

L01XK Poly (ADP-ribose) polymerase (PARP) inhibitors

:L01XK01 Olaparib :L01XK02 Niraparib :L01XK03 Rucaparib :L01XK04 Talazoparib :L01XK05 Veliparib :L01XK06 Pamiparib :L01XK07 Senaparib :L01XK52 Niraparib and abiraterone

L01XL Antineoplastic cell and gene therapy

:L01XL01 Sitimagene ceradenovec :L01XL02 Talimogene laherparepvec :L01XL03 Axicabtagene ciloleucel :L01XL04 Tisagenlecleucel :L01XL05 Ciltacabtagene autoleucel :L01XL06 Brexucabtagene autoleucel :L01XL07 Idecabtagene vicleucel :L01XL08 Lisocabtagene maraleucel :L01XL09 Tabelecleucel :L01XL10 Nadofaragene firadenovec :L01XL11 Lifileucel :L01XL12 Obecabtagene autoleucel

L01XM Isocitrate dehydrogenase (IDH) inhibitors

:L01XM01 Enasidenib :L01XM02 Ivosidenib :L01XM03 Olutasidenib :L01XM04 Vorasidenib

L01XU Other antineoplastic agents (cont.)

:Empty group

L01XX Other antineoplastic agents

:L01XX01 Amsacrine :L01XX02 Asparaginase :L01XX03 Altretamine :L01XX05 Hydroxycarbamide :L01XX07 Lonidamine :L01XX08 Pentostatin :L01XX10 Masoprocol :L01XX11 Estramustine :L01XX16 Mitoguazone :L01XX18 Tiazofurine :L01XX23 Mitotane :L01XX24 Pegaspargase :L01XX27 Arsenic trioxide :L01XX29 Denileukin diftitox :L01XX33 Celecoxib :L01XX35 Anagrelide :L01XX36 Oblimersen :L01XX40 Omacetaxine mepesuccinate :L01XX41 Eribulin :L01XX44 Aflibercept :L01XX46 Olaparib :L01XX52 Venetoclax :L01XX53 Vosaroxin :L01XX57 Plitidepsin :L01XX58 Epacadostat :L01XX66 Selinexor :L01XX67 Tagraxofusp :L01XX69 Lurbinectedin :L01XX72 Tazemetostat :L01XX73 Sotorasib :L01XX74 Belzutifan :L01XX75 Tebentafusp :L01XX77 Adagrasib :L01XX78 Navitoclax :L01XX79 Eflornithine :L01XX80 Imetelstat :L01XX81 Nirogacestat :L01XX82 Darinaparsin :L01XX83 Para-toluenesulfonamide :L01XX84 Pelabresib :L01XX85 Idroxioleic acid :L01XX86 Calaspargase pegol :L01XX87 Revumenib :QL01XX91 Tigilanol tiglate :QL01XX92 Verdinexor

L01XY Combinations of antineoplastic agents

:L01XY01 Cytarabine and daunorubicin :L01XY04 Bifikafusp alfa and onfekafusp alfa

References

::callout[type=info title="Wikipedia Source"] This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page. ::